CP
AURA icon

Caligan Partners’s Aura Biosciences AURA Stock Holding History

Caligan Partners’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.5M Buy
4,298,248
+4,068,384
+1,770% +$29.1M 1.44% 17
2026
Q1 		$1.54M Buy
+229,864
New +$1.32M 0.1% 27
2025
Q4 		– Sell
-227,174
Closed -$1.4M – 27
2025
Q3 		$1.4M Buy
227,174
+27,174
+14% +$178K 0.18% 18
2025
Q2 		$1.25M Buy
+200,000
New +$1.17M 0.24% 17

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Caligan Partners's AURA Position: Q2 2026 in Review

Caligan Partners increased its Aura Biosciences (AURA) stake by 1,770% in Q2 2026, buying an estimated $29.1M and bringing the position to 4,298,248 shares worth $30.5M. The position accounts for 1.44% of the portfolio, ranked #17.

Caligan Partners first reported a position in AURA in Q2 2025 and has held it in 4 quarters since. 146 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Caligan Partners held 4,298,248 shares of Aura Biosciences worth $30.5M as of Q2 2026.
  • Caligan Partners bought 4,068,384 Aura Biosciences shares in Q2 2026, an estimated $29.1M.
  • Aura Biosciences made up 1.44% of Caligan Partners's portfolio in Q2 2026, its #17 holding.
  • Caligan Partners first reported a position in Aura Biosciences in Q2 2025 and has held it in 4 quarters since.
  • 146 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Caligan Partners's 13F filing for Q2 2026, filed 14 Aug 2026.